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High risk human papillomaviruses (HPV) cause 5% of all cancer
worldwide, and the low risk types are responsible for considerable
morbidity (Parkin and Bray, 2006). While the HPVs do not produc-
tively infect non-human species and vice versa (Koller and Olson,
1972), a plethora of animal papillomaviruses induce papillomas and
cancer that result in distress to the host and signiﬁcant agricultural
losses (Bernard et al., 2010; Munday and Kiupel, 2010). Ten different
genotypes of bovine papillomavirus (BPV) have been described. BPV
infection causes skin warts and urinary bladder cancer (BPV1 and
BPV2), papillomatosis and cancers of the upper gastrointestinal tract
(BPV4), papillomatosis of the penis (BPV1), teats and udder (BPV1,
BPV5 andBPV6) (Nasir and Campo, 2008). The development of cancers
can be enhanced by an interaction between BPV infection andconsumption of carcinogens and immunosuppressantswithin bracken
fern (Campo, 1987). Horses, donkeys and mules can develop sarcoids
upon exposure to BPV1 and BPV2 that are locally invasive, refractory to
treatment and often require culling of the animal (Nasir and Campo,
2008). Tumors can also be induced by challenge of genital mucosa or
urinary bladder of cattle (Olson et al., 1962). Canine oral papilloma-
virus (COPV) produces papillomas in the oropharynx of dogs that can
spread to other regions and even progress to squamous cell carcinoma
(SCC) (Bregman et al., 1987). A number of other canine papillomavi-
ruses (CfPV2, CfPV3 and CfPV4) have also been associated with SCC,
and feline (FdPV1 and FdPV2) and cottontail rabbit (CRPV) papillo-
maviruses can produce SCC in their respective hosts (Munday and
Kiupel, 2010).
Licensed vaccines for the prevention of HPV infection are com-
prised of virus-like particles (VLPs) derived by recombinant expres-
sion of major capsid protein L1 (Roden and Wu, 2006). The impetus
for their development came from the protection of rabbits, dogs and
cattle from viral challenge by prior vaccination with L1 VLP generated
from the genotype of papillomavirus used for challenge (Breitburd
et al., 1995; Christensen et al., 1996; Kirnbauer et al., 1996; Suzich
et al., 1995). Passive transfer studies in the rabbit and dog models
demonstrated that the neutralizing antibodies generated by L1 VLP
vaccination are sufﬁcient to mediate protection that is type restricted,
although the minimal titers required for protection are not currently
known (Breitburd et al., 1995; Suzich et al., 1995). Type-restriction in
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development of a nonavalent L1 VLP formulation to broaden coverage
to themajority of oncogenic HPV genotypes (Campo and Roden, 2010;
Munoz et al., 2004). While formalin-treated papillomavirus vaccines
have been used for veterinary applications, there are currently no
commercial VLP-based vaccines for use in animals (Bell et al., 1994;
Olson et al., 1962, 1968).
The diversity of papillomaviruses associated with disease in
agriculturally signiﬁcant and other domesticated species suggested
that highly multivalent L1 VLP vaccines might be required even for
individual species. Another possible prophylactic vaccine antigen is
the minor capsid protein L2 (Campo and Roden, 2010). Studies in the
cattle and rabbit challenge models suggest that vaccination with the
amino terminus of L2 comprising residues 11–200 or 1–88 produced
recombinantly in bacteria is protective (Campo, 1994; Chandrachud et
al., 1995; Gambhira et al., 2007a). Furthermore vaccination of rabbits
with residues 1–88 of L2 induces broadly cross-neutralizing antibodies
and is sufﬁcient for protection (Gambhira et al., 2007a; Pastrana et al.,
2005). Vaccination of rabbits with L2 derived from HPV16 protects
against challenge with either CRPV or ROPV, suggesting the possibility
of broad protection using this antigen (Gambhira et al., 2007a). While
neutralizing antibodies generated by L1 VLP recognize conformational
epitopes, the neutralizing epitopeswithin L2 are predominantly linear
(Christensen et al., 1991; Gambhira et al., 2007b; Knowles et al., 1997;
Lin et al., 1992; Pilacinski et al., 1986). Thus, unlike L1 VLP, the breadth
of protection can potentially be further enhanced by generating a
multimer of the protective epitope derived from diverse papilloma-
virus types (Jagu et al., 2009). Herein we have explored the potential
of this approach to derive a multimeric L2 vaccine for prevention of
animal papillomavirus infections, and to examine the neutralizing
antibody titers associated with protection.
Results and discussion
Passive transfer studies of L1 VLP or L2-speciﬁc neutralizing IgG
protects naïve animals from experimental papillomavirus challenge
suggesting that antibodies are at least sufﬁcient to mediate immunity.
However, the minimal serum titer of neutralizing antibodies neces-
sary to effect protection against papillomavirus challenge is not
currently deﬁned, although recent studies suggest that it is very
low (Day et al., 2010). To examine this question we exploited serumFig. 1. Summary of three previously published BPV4 challenge studies in cattle receiving p
(Control a, Control b and Control c) received no vaccinations prior to challenge. The following
L2 201–326 fused with GST), L2c (BPV4 L2 327–454 fused with GST), and full length BPV4 L
peptide 11 comprising residues 101–120 of BPV4 L2 (TGVPIDPAVPDSSIVPLLES), peptide 14 c
L2 residues 151–170 (EVTIGDIEEPPILEVVPETH), or a combination of the 3 peptides (Campo e
(Kirnbauer et al., 1996). Left panel: Calves were vaccinated twice a month apart with 50 μg o
5:5:5:1) or with 330 μg L2c, all formulated in alhydrogel (Campo, 1997). Middle panel: Calves
14, peptide 16, or all three together, in each case formulated in alhydrogel (Campo et al., 1997
or 200 μg of L1+L2 VLPs, both formulated in alhydrogel (Kirnbauer et al., 1996). All animals
virions.samples derived in earlier published challenge studies in which calves
vaccinated twice with various BPV4 L2 polypeptides (Campo et al.,
1997; Chandrachud et al., 1995) or VLPs (Kirnbauer et al., 1996) were
subsequently challenged on the soft palate at ten sites with 1011
native BPV4 virions, and followed for the development of papillomas
(Fig. 1). These prior studies demonstrated that BPV4 VLPs and some,
but not all L2 polypeptides protected the calves from experimental
BPV4 challenge, thus providing an opportunity to correlate degree of
protection with potentially relevant immune parameters, including
BPV4 L1 and L2-speciﬁc and neutralizing antibody levels.
Initially, the ability of the vaccination with BPV4 L2-derived
peptides or VLPs to induce speciﬁc serum antibody titers was
examined by ELISA using full length BPV4 L2 protein puriﬁed from
E. coli using a hexahistidine tag (Fig. 2). Cattle vaccinated with L2a
(BPV4 L2 11–200 fused with GST), L2b (BPV4 L2 201–326 fused
with GST), L2c (BPV4 L2 327–454 fused with GST), or L2a+b+c
(a combination of L2a, L2b, L2c and full length BPV4 L2 in the ratio
5:5:5:1) all formulated in alum adjuvant generated detectable titers
of BPV4 L2-reactive serum IgG antibodies (Campo et al., 1997;
Chandrachud et al., 1995). Conversely, these antibodies were lacking
in the control animals and those vaccinated with either L1 only VLPs
or VLPs containing L1 and L2. The failure of immunization with
L1+L2 VLPs to induce signiﬁcant L2-speciﬁc antibody responses has
been observed previously (Roden et al., 2000), and might suggest that
themajority of L2 is buried below the capsid surface (Day et al., 2008),
and, as a minor and widely spaced constituent of the capsid, L2 is
immunologically subdominant to L1 (Chackerian et al., 2001).
Unfortunately native BPV4 virions do not produce a readily
detectable phenotype upon infection of cells in tissue culture that
can be utilized in the measurement of viral titers and neutralizing
antibodies. A model in which bovine fetal palate chips are infected in
vitro with native BPV4 in the presence of serum and then engrafted
subcutaneously into the ﬂank of nude mice has demonstrated that
vaccination with BPV4 L2 induces neutralizing antibodies (Gaukroger
et al., 1996). However, to simplify the measurement of neutralizing
antibody titers we developed BPV4 pseudovirions that encapsidate
a reporter plasmid expressing secreted alkaline phosphatase (Buck
et al., 2004; Pastrana et al., 2004). The BPV4 L1 and L2 genes were
synthesized as codon-modiﬁed constructs and each inserted into the
pcDNA3.1(−) vector to enhance their expression in mammalian cells
as previously described for BPV1 (Buck et al., 2004). The BPV4 L1 androphylactic vaccination with BPV4 L2 peptides or VLP. Animals in the control groups
polypeptide immunogens were used: L2a (BPV4 L2 11–200 fused with GST), L2b (BPV4
2 fused to GST. The following peptides were coupled to KLH and used as immunogens:
omprising L2 residues 131–151 (PGAEIEIIAEVHPPPVYEGPE), and peptide 16 comprising
t al., 1997). BPV4 L1 only or L1+L2 VLPs were prepared using recombinant baculovirus
r 10 μg of L2a+b+c (a combination of L2a, L2b, L2c and full length BPV4 L2 in the ratio
were vaccinated twice amonth apart with 330 μg of L2a, or 50 μg of peptide 11, peptide
). Right panel: Calves were vaccinated twice a month apart with 150 μg of BPV4 L1 VLPs
were challenged on the soft palate two weeks after the ﬁnal vaccination with 1011 BPV4
Fig. 2. Assessment by ELISA of BPV4 L2-speciﬁc serum immunoglobulin responses to vaccination. Sera from cattle vaccinated with BPV4 L2-derived peptides or VLPs from the prior
studies summarized in Fig. 1 were tested for speciﬁc serum antibody titers by ELISA using full length BPV4 L2 protein. The serum samples tested in the left panel, middle panel and
right panel are described respectively in (Campo et al., 1997; Chandrachud et al., 1995; Kirnbauer et al., 1996).
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transfected in to 293TT cells and after 72 h the cells were harvested
and lysedwith detergent (Supplementary Fig. 1). The cell lysates were
separated by density centrifugation and the fractions typically
containing particles analyzed by SDS-PAGE and Coomassie blue
staining and Western blot for the presence of either BPV4 L1 or L2
(Supplementary Fig. 1) and titrated for their ability to transfer the
reporter plasmid to fresh 293TT cells. The fraction containing the
greatest titer for delivery of the secreted alkaline phosphatase (SEAP)
reporter exhibited the highest level of L2 and a high level of L1, and
thus it was utilized for the development of an in vitro neutralization
assay for BPV4.
The in vitro neutralization assay for BPV4was thus utilized to assay
the titers of the sera of the calves vaccinated with the various BPV4
L2 constructs or VLPs (Campo et al., 1997; Chandrachud et al., 1995;
Kirnbauer et al., 1996). Fig. 3 shows that the sera of calves vaccinated
with BPV4 L1 VLPs or L1+L2 VLPs all exhibited high neutralizing
antibody titers that were absent from the sera of control animals
(Kirnbauer et al., 1996). Interestingly, sera of calves vaccinated with
BPV4 L2a, alone or mixed with other L2-derived peptides, contained
much lower levels of BPV4 neutralizing antibodies than the sera
of VLP-vaccinated calves (Campo et al., 1997; Chandrachud et al.,
1995). BPV4 neutralizing antibodies were not detected in the sera of
calves vaccinated with BPV4 L2c, or KLH-coupled small synthetic L2Fig. 3. Assessment of titers for BPV4 pseudovirion neutralization of sera of vaccinated cattle
vitro neutralization titers using BPV4 pseudovirions carrying the secreted alkaline phosphata
as in Fig. 1 (described respectively in Campo et al., 1997; Chandrachud et al., 1995; Kirnbaupeptides (peptide 11 comprising BPV4 L2 residues 101–120, peptide
14 comprising L2 residues 131–151, or peptide 16 comprising L2
residues 151–170 or a mixture of all three), although we cannot rule
out the possibility of neutralizing antibody titers of b25 due to non-
speciﬁc background at high serum concentrations.
These in vitro neutralization titers for BPV4 were compared to the
previously published outcome of challenge of the same calves with
BPV4 two weeks after their second immunization (Campo et al.,
1997; Chandrachud et al., 1995; Kirnbauer et al., 1996). Vaccination
with BPV4 L1 VLP protected all 8 animals against papillomas after
BPV4 challenge, whereas 2 of 7 calves vaccinated with L1+L2 VLPs
developed a small number of papillomas, and 9 of 10 control animals
developed papillomas, mostly in larger numbers (Fig. 1). However, all
of the VLP immunized animals developed robust serum titers of BPV4
neutralizing antibodies that were L1-speciﬁc as determined by BPV4
L1 VLP ELISA (not shown).
Vaccination of calves with 50 μg of L2a+b+c covering the entire
protein protected 10 of 12 calves from experimental challenge with
BPV4 (Fig. 1). Conversely, 9/11 control animals developed multiple
papillomas. Low titers of BPV4 neutralizing antibodies were detected
in the sera of all but three calves vaccinated with 50 μg of L2a+b+c
in alum, and none of the sera from the control animals exhibited
detectable neutralizing antibody titers. Surprisingly, none of the
animals vaccinated with 10 μg of L2a+b+c contained detectable. Sera from cattle vaccinated with BPV4 L2-derived peptides or VLPs were tested for in
se reporter. The serum samples tested in the left panel, middle panel and right panel are
er et al., 1996).
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free of papillomas after experimental BPV4 challenge (Campo et al.,
1997; Chandrachud et al., 1995).
In the prior studies an effort was made to map the protective
epitopes (Campo et al., 1997; Chandrachud et al., 1995). The L2b
peptide was not found to be immunogenic in the calves vaccinated
with L2a+b+c, and thus protection studies were performed with
the L2a and L2c antigens. Vaccination with L2c polypeptide was not
protective as papillomas developed in 10 of 12 vaccinated calves, and
no neutralizing antibodies were detected in their sera, despite robust
L2-speciﬁc antibody titers measured by L2 ELISA. Conversely, none of
6 calves vaccinated with L2a developed papillomas after challenge,
and all 6 contained detectable titers of BPV4 neutralizing antibodies,
albeit much lower than those observed for VLP-vaccinated animals
(Fig. 1).
Mapping of the epitopes recognized by animals vaccinated with
L2a using overlapping peptides spanning residues 1–200 of BPV4 L2
indicated recognition of peptide 11 comprising residues 101–120
(TGVPIDPAVPDSSIVPLLES), peptide 14 comprising L2 residues 131–
151 (PGAEIEIIAEVHPPPVYEGPE), and peptide 16 comprising L2
residues 151–170 (EVTIGDIEEPPILEVVPETH) by ELISA (Knowles
et al., 1997). Calves were vaccinated with each peptide individually,
a control peptide, or a mixture of all three peptides coupled to KLH,
and all animals receiving an L2-derived peptide developed reactive
serum antibodies as determined by L2 ELISA. Calves vaccinated with
control peptide, peptide 11 alone, or peptide 16 alone developed
papillomas after experimental challenge (5/6, 5/6, and 4/6 respec-
tively, Fig. 1), whereas calves vaccinated with peptide 14 alone or
the mixture of peptides 11, 14 and 16 were protected as only 1/6
and 0/6 animals developed papillomas after experimental challenge
with BPV4. This earlier study indicated that peptide 14 is a protective
epitope (Campo et al., 1997), although no in vitro neutralizing
antibodies were detected in the sera of these animals (Fig. 3). Since
passive transfer of an L2-speciﬁc neutralizing monoclonal antibody
(Gambhira et al., 2007b) or small volumes of immune serum (Day
et al., 2010) confers protection against experimental challenge in a
mouse model, this suggests that either very low levels of neutralizing
antibodies are sufﬁcient for protection and that our in vitro
neutralization assay lacks the sensitivity to detect these titers, or
that T cell-based responses to L2 might also contribute to protection.
Indeed, it is noteworthy that three of the 6 animals vaccinated with
peptide 14 developed small translucent dome-shaped lesions termed
plaques (typically seen before the appearance of typical frondy
papillomas actively producing virus), yet they did not develop
papillomas (Campo et al., 1997). This suggests the possibility of
immune-mediated clearance of these plaques, but it is hard to exclude
that partial neutralization of the inocula resulted in low level abortive
infections. Jarrett et al. vaccinated cattle with BPV2 L2 90–467 and
this was not protective, but it did enhance regression of papillomas
(Jarrett et al., 1991). This is consistent with studies in BPV1 mapping
the location of the neutralizing epitopes principally to the ﬁrst 88
residues of BPV1 L2 (Pastrana et al., 2005), and raises the possibility of
a T cell-mediated clearance through recognition of residues 90–467.
Conversely, vaccination with L2 1–88 or 11–200 of CRPV protects
rabbits from cutaneous challenge with CRPV virions but not CRPV
genomic DNA, and the resulting papillomas grow at the same rate
in L2-vaccinated and control NZW rabbits (Gambhira et al., 2007a).
The latter discrepancy might reﬂect either the location of the T cell
epitopes of CRPV L2 after residue 200, or an incomplete late
expression program for CRPV in domestic NZW rabbits as compared
with cottontail rabbits, the natural host for this virus.
While several studies raise the possibility that neutralizing
epitopes are present further toward the C-terminus of L2 (Campo et
al., 1997; Christensen et al., 1991; Kawana et al., 1999; Lin et al., 1992),
vaccination with concatemers of L2 11–88 derived from diverse HPV
genotypes induces robust titers of antibodies neutralizing numerousmedically signiﬁcant HPV genotypes within the mucosatropic α
species of papillomaviruses (Jagu et al., 2009). Since the papilloma-
virus genotypes impacting agricultural and domesticated animals,
notably cattle and dogs, belong to distinct species of papillomaviruses
(Bernard et al., 2010), we generated a multimer of L2 residues
spanning the putative furin cleavage site to residue 88 derived from
three bovine and three canine papillomavirus genotypes; BPV1, BPV4,
BPV5, COPV, CaPV2 and CaPV3 (Richards et al., 2006). The construct
was generated by direct synthesis with codon utilization optimized
for bacterial expression and inserted into the expression vector
pET28a in frame with a hexahistidine tag. This construct, herein
termed ‘animalx6’, was produced in E. coli Rosetta cells upon IPTG
induction and afﬁnity puriﬁed under denaturing conditions using a
Ni-NTA column and exchanged into PBS by dialysis.
The immunogenicity of the animalx6 protein was tested in Balb/
c mice (Fig. 4). Two weeks after three immunizations of 25 μg
of protein formulated in alum or RIBI adjuvant system, sera was
harvested from 5 mice and tested for in vitro neutralizing antibody
titer. Additional mice were vaccinated in parallel with either Sigma
adjuvant system alone or 25 μg of BPV4 L1 VLP in alum, or BPV1 L1 VLP
in alum on the same schedule. The sera of mice vaccinated with BPV1
L1 VLP exhibited high titers of neutralizing antibody against BPV1,
but not BPV4 or HPV16 (Fig. 4). Likewise, the sera of mice vaccinated
with BPV4 L1 VLP had consistently high neutralizing antibody
titers for BPV4, but none was detected for neutralization of BPV1 or
HPV16, as expected for the type-restricted protection induced by L1
VLP vaccination. Interestingly, sera from mice vaccinated with the
animalx6 protein neutralized BPV1, BPV4 and HPV16, with generally
higher titers in the sera of mice vaccinated using RIBI as compared to
the alum formulation of the animalx6 antigen (Fig. 4). The antisera
from mice vaccinated with the animalx6 antigen in either adjuvant
also contained robust IgG titers that recognized COPV pseudovirions
by ELISA. Pooled antisera from mice vaccinated with the animalx6
antigen in either alum or RIBI adjuvant were able to neutralize wart-
derived COPV virions in vitro at 1:200, demonstrating that neutral-
ization is not an artifact of the pseudovirion system. Therefore, the
animalx6 vaccine induces a neutralizing antibody response against a
broad range of papillomavirus types.
The BPV/cattle and COPV/dog challenge models require consider-
able infrastructure and resources, and therefore we sought an
alternative approach to test the protective efﬁcacy of the animalx6
vaccine. Roberts et al. have developed a mouse vaginal challenge
model using HPV pseudovirions delivering a reporter construct
(Roberts et al., 2007). Since BPV1 and BPV2 infect mouse cells
(Dvoretzky et al., 1980), we examinedwhether pseudovirions derived
from BPV1, BPV4 or COPV and carrying the luciferase reporter could
detectably infect the mouse vaginal tract. Only BPV1 pseudovirions
generated a detectable infectious signal, whichmay reﬂect differences
in efﬁciency of pseudovirion assembly or tropism since BPV1 has been
shown to infect the vagina, as well as skin and urinary bladder of cattle
(Olson et al., 1962). These ﬁndings suggested that vaginal challenge of
mice with BPV1 pseudovirions might provide a feasible alternative to
the challenge of calves with BPV1 virus.
The groups of mice vaccinated with animalx6 protein formulated
in either alum or RIBI, RIBI alone or L1 VLPs derived from BPV1 or
BPV4 and formulated in alum were thus challenged intra-vaginally
with BPV1 pseudovirions carrying the luciferase reporter. Three days
later, the extent of infection was assayed by instillation of luciferin
and imaging of the resultant bioluminescence. In mice receiving
RIBI alone, a high bioluminescent signal was observed, and this was
absent from mice that had been vaccinated with BPV1 VLPs (Fig. 5).
A prior study in cattle by Jarrett et al. indicated that vaccination
with virions of one BPV type generally failed to protect against
challenge by other BPV genotypes, although there was signiﬁcant
cross-protection between BPV1 and BPV2 (Jarrett et al., 1990; Shafti-
Keramat et al., 2009). While BPV1 L1 VLP vaccination completely
Fig. 4. Immune response of mice vaccinated with a multimeric L2 vaccine derived from six animal papillomaviruses. Sera frommice vaccinated three times at 2 week intervals with
BPV4 or BPV1 L1 VLPs formulated in alum or themultimeric L2 vaccine (animalx6) formulated in either alum or RIBI adjuvant were tested for in vitro neutralization titers using BPV1
pseudovirions (panel A), BPV4 pseudovirions (panel B) or HPV16 pseudovirions (panel C), each carrying a secreted alkaline phosphatase reporter. Sera were also analyzed using
COPV pseudovirion ELISA (panel D).
Fig. 5. Protection of mice from genital challenge with BPV1 by L1 VLP or L2 multimer
vaccines. Mice vaccinated three times at 2 week intervals with BPV4 or BPV1 L1
VLPs formulated in alum or the multimeric L2 vaccine (Animalx6) formulated in either
alum or RIBI adjuvant were challenged with BPV1 pseudovirions carrying a luciferase
reporter construct. Infection was assessed bymeasuring bioluminescence at 3 days post
challenge.
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reduced BPV1 pseudovirus infection. Conversely, no signiﬁcant
infection was observed in either group of mice vaccinated with the
animalx6 protein in alum or RIBI (pb0.01), as observed in the group
vaccinated with BPV1 L1 VLPs.
These ﬁndings support earlier studies suggesting that immuniza-
tion with concatemers of conserved polypeptides derived from the
N-terminus of L2 (between the putative furin cleavage site and
residue 88, see Supplementary Fig. 2) has promise as a prophylactic
vaccine for the prevention of disease in animals caused by diverse
papillomavirus types (Chandrachud et al., 1995; Jagu et al., 2009).
Vaccination with L2 induces neutralizing antibodies of signiﬁcantly
lower titers than L1 VLP, but they are nonetheless protective in several
animal models, and more broadly acting than L1 VLP-induced
responses (Campo and Roden, 2010). While L1 VLP vaccination elicits
lasting immunity to natural infection, it remains unclear how long
L2 vaccination maintains protection. However, protection of cattle
from experimental BPV4 challenge one year after vaccination with L2
has been observed (McGarvie et al., 1994). Although an additional
contribution by T cell-mediated responses remains a possibility
(Jarrett et al., 1991), passive transfer studies have indicated that
immunity generated by L2 or L1 VLP vaccination can be mediated by
48 S. Jagu et al. / Virology 420 (2011) 43–50neutralizing antibodies alone (Day et al., 2008, 2010; Gambhira
et al., 2007b; Schiller et al., 2010). That no therapeutic effect has been
demonstrated for an L1 VLP vaccine in humans (Hildesheim et al.,
2007; Koutsky et al., 2002) suggests that aminimal titer of neutralizing
antibodies may be required to provide sterilizing immunity.
Although it remains possible that a capsid antigen-speciﬁc cytotoxic T
cell response could also contribute to protection, vaccinationwithHPV6
L2 (fused with E7) in a potent adjuvant failed to enhance the regression
rate of genital warts (Vandepapeliere et al., 2005), and vaccinationwith
HPV16 L2 (fusedwith E6 and E7) failed to trigger dramatic regression of
HPV16+ high grade VIN/VaIN (Davidson et al., 2003; Fiander et al.,
2006; Smythet al., 2004), althoughboth induced avaccine-speciﬁc T cell
response. Likewise, vaccination with L1 VLP also induces a T cell
response in patients (Pinto et al., 2003, 2006) without apparently
impacting existing disease (Hildesheim et al., 2007; Koutsky et al.,
2002). Nevertheless, a more detailed subset analysis may reveal a
therapeutic effect and/or that capsid antigen-speciﬁc T cell-mediated
responses do contribute to protection, as has been suggested from some
animal and clinical studies (Govan et al., 2008; Jarrett et al., 1991;
Koutsky et al., 2002; Zhang et al., 2000).
No neutralizing antibody was detected in a number of cattle
vaccinated with L2 polypeptides and immune to experimental BPV4
challenge. If protection in these animals is not mediated by T cell-
based immunity, then it is likely that the current in vitro neutralizing
assay lacks the sensitivity to detect low titer yet protective antibody
levels, at least for those speciﬁc for L2. This may reﬂect lower avidity
of L2 as compared to L1-speciﬁc antibody and/or differing mecha-
nisms and timing of neutralization in vivo as compared to infection of
the 293TT cells used in the in vitro neutralization assays (Kines et al.,
2009). These observations suggest that such low titer protective
responses might be better detected by passive transfer into mice prior
to challenge (Day et al., 2010). T cell responses may also contribute to
protection and additional studies are warranted to deﬁne mecha-
nisms and relevant protective epitopes.
Methods
Production of the animalx6 protein
L2 residues spanning the putative furin cleavage site to residue 88
derived from three bovine and three canine papillomavirus genotypes;
BPV1, BPV4, BPV5, COPV, CaPV2 and CaPV3 were codon-modiﬁed and
the sequence (see Supplementary information and Supplementary
Fig. 2) was synthesized by Biobasic Inc, and then subcloned as a
BamHI-XhoI fragment into the pET28a vector (Novagen) for expres-
sion in E. coli as a hexahistidine-tagged recombinant polypeptide
expressed in E. coli BL21 (Rosetta cells, Novagen) (Pastrana et al.,
2005). The hexahistidine-tagged recombinant L2 polypeptide ani-
malx6 was afﬁnity puriﬁed by binding to a nickel-nitrilotriacetic acid
(Ni-NTA) column (Qiagen) in 8 M urea (using the QiaExpressionist
standard puriﬁcation protocol for denaturing conditions) and then
dialyzed in cassettes (Pierce) against Dulbecco's phosphate buffered
saline (PBS). Purity was monitored by SDS-PAGE and protein
concentration determined by bicinchoninic acid test (Pierce) using a
bovine serum albumen standard (Jagu et al., 2009).
Neutralization assays
The BPV1 and HPV16 pseudovirion in vitro neutralization assays
were performed as described earlier (Jagu et al., 2009; Pastrana et al.,
2004) and the secreted alkaline phosphatase content in the clariﬁed
supernatant was determined using the p-Nitrophenyl phosphate
substrate (Sigma, St. Louis, MO) dissolved in diethanolamine and
absorbance measured at 405 nm. Constructs and detailed protocols
for the preparation of the pseudovirions can be found at http://home.
ccr.cancer.gov/lco/. Titers were deﬁned as the reciprocal of the highestdilution that caused a 50% reduction in A405. For the generation of
BPV4 pseudovirions, the codon-modiﬁed BPV4 L1 and L2 sequences
(see Supplementary information) were synthesized by Blue Heron
Biotech and each sublconed into pcDNA3.1(−) using XbaI. The
BPV4 L2 sequence was also subcloned into pET28a for expression in
bacteria, and generated mouse antiserum to full length 6His-tagged
BPV4 L2 by vaccination of Balb/c mice three times with 25 μg of
antigen in RIBI adjuvant. BPV4 pseudovirions were prepared as
described previously by co-transfection of the BPV4 L1 and L2
expression plasmids with the pYSEAP reporter construct into 293TT
cells. Expression of the BPV4 L1 and L2 proteins was veriﬁed by
Western blot using mouse monoclonal antibody 1H8 (Chemicon) to
L1 andmouse antiserum to 6His-BPV4 L2 respectively. BPV1 and BPV4
L1 VLPs were generated by transfection of the 293TT cells with only the
L1 expression vector. The COPV L1 and L2 codonmodiﬁed sequences are
available atGenbank accession numbers JN638232 (COPV L1ADAP) and
JN638233 (COPV L2 ADAP).
COPV neutralization assay
Canine CPEK cells were trypsinized and seeded at 5×105 per well
in 6-well plates. The next day, cultures were infected with 200 wart-
derived COPV (CPV1) particles per cell in 1 ml of medium in the
presence of PBS control or indicated diluted antisera. Cultures
received 2-ml additional medium 24 h post-infection. Total RNAs
were isolated using TRIzol (Invitrogen) according to the manufac-
turer's instructions. All reactions containing RNAs from virus-infected
cells were performed in triplicate. cDNA were made using Super-
Script® III One-Step RT-PCR System (Invitrogen). SYBR Green real-
time qRT-PCR was performed on the Bio-Rad iCycler MyiQ (BioRad)
for quantiﬁcation of viral E1^E4 mRNA. The primers used to detect for
CPV1 E1^E4 mRNA were: sense primer, 5′-GCTAGAAAAGTGCCGCCG
GA-3′, anti-sense primer, 5-TGGGGAACCGCGACGACCTC-3′. The canine
HPRT mRNA (sense primer, 5′-CTCACTATGATCCACCACG-3′, anti-sense
primer, 5-TAGCCTCCATAACCTCCAC-3′) was used as internal RNA
control for the relative quantiﬁcation. Primer concentration in the
reactionmixturewas 5 pmol/ml. Cycling conditionswere95° for 10 min
followed by 42 cycles of 94° for 15 s and 60° for 1 min. All samples were
run in triplicate. Relative quantities of viral target cDNA were
determined using iQ™5 Optical System Software (BioRad).
Enzyme-linked immunosorbent assays (ELISA)
Immobilon plates (Nunc) were coated with 100 ng/well of 6His-
BPV4 L2 (prepared in E. coli) or BPV4 L1 VLPs (produced in 293TT) or
COPV L1/L2 pseudovirions (Genbank accession numbers JN638232
and JN638233) in PBS overnight at 4 °C. Wells were then blocked with
SeaBlock (Pierce) for 1 h at room temperature, and incubated with
2-fold dilutions of bovine sera for 1 h at room temperature, or blocked
with BSA for 1 h at room temperature, and incubated with 2-fold
dilutions of mouse antisera for 1 h at room temperature. Following a
wash step with PBS-0.01% (v/v) Tween 20, either peroxidase-labeled
rabbit anti-bovine Ig (KPL) diluted 1:5000 in SeaBlock was added for
1 h, or peroxidase-labeled anti-mouse Ig (GE) diluted 1:5000 in 1%
BSA-PBS was added for 1 h. The plates were then washed and
developed with 2, 2′-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid
solution (Roche) for 10 min and the absorbance at 405 nm read with
Benchmark Plus (Biorad) microtiter plate reader.
Mouse vaccination and challenge
Studies were performed with the approval of the Johns Hopkins
University Animal Care and Use Committee. Female Balb/c 6–8 weeks
old mice were purchased from the National Cancer Institute
(Frederick, MD, USA) and kept in the animal facility of the Johns
Hopkins University (Baltimore, MD, USA) at least one week prior to
49S. Jagu et al. / Virology 420 (2011) 43–50use. The mice were vaccinated in groups of 5 animals three times
at two week intervals s.c. with 25 μg of L2 animalx6 protein in 50 μg
of aluminum hydroxide (alum) alone, or with RIBI adjuvant (2%
squalene, 5 μg MPLA, 5 μg trehalose dicorynomycolate, Sigma S6322)
or with 5 μg of BPV1 L1 VLP or BPV4 L1 VLP adsorbed on to alum
(50 μg). Serum samples were obtained by tail vein bleeds two weeks
and four months after the ﬁnal immunization. Two weeks after the
ﬁnal immunization, mice received 3 mg of Depo-provera (Pﬁzer)
diluted in 100 μl of sterile PBS in a subcutaneous injection. Four days
later the pseudovirus challenge inoculum was administered as a 40 μl
dose composed of puriﬁed BPV4 pseudovirus carrying the luciferase
reporter gene mixed in 2% (v/v) carboxymethyl cellulose (CMC)
(Sigma C5013). The virus was delivered in two doses. Half was
deposited into mouse vagina by using a M50 positive displacement
pipette (Gilson). A cytobrush cell collector was inserted in the vagina
and turned clockwise and counter clockwise for 10 times and the
remaining 20 μl introduced. Three days later, the mice were
anesthetized and luciferin (20 μl at concentration of 7 mg/ml) was
deposited intravaginally, and their images were acquired for 10 min
using Xenogen IVIS200.
Statistical analysis
Comparison of Log10 transformed titers by ANOVAwith Bonferroni
correction for multiple comparisons and graphical presentation of
titers as box/whisker plots were performed using GraphPad Prism 4
software. Signiﬁcance was set a pb0.05. Titers less than 25 were
arbitrarily set at 10 for graphical purposes.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.endend.2010.04.036.
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